Trials / Completed
CompletedNCT02153268
Filling Bone Defects/Voids With Autologous BonoFill For Maxillofacial Bone Regeneration
Phase I/II Open Label FIH Single Center Clinical Study Aimed to Evaluate the Safety and the Efficacy of BonoFill in Reconstructing the Bone.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- BonusBio Group Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Phase I/II open label first in human single center clinical study, is to evaluate the safety and the efficacy of BonoFill as bone filler containing the patient own (autologous) adipose tissue derived cells (HATDCs) in reconstructing the Bone Void in the maxillofacial area approximately 6 month follow up after implantation in the following two clinical indications: 1. Bone augmentation (e.g. sinus augmentation) 2. Bone grafting after removal of cysts from jaws
Detailed description
Primary endpoint: The implantation of BonoFill to the maxillary or mandible defect/void is safe under the following conditions: No chronic bone infection (Osteomyelitis); no significant changes in complete blood count (CBC) and in general health. Secondary endpoint: The implantation of BonoFill to the maxillary or mandible void is efficient under the following conditions: Following BonoFill implantation, the bone regeneration in the operated site was significantly accelerated. Also, the bone defects/voids were filled with a significant amount of bone tissue.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Single Arm - Liposuction procedure and BonoFill transplantation will be done for all subjects on study | Liposuction - will be performed on Visit 2, BonoFill will be based on subject's autologous Human Adipose Tissue Derived Cells (HATDCs). BonoFill Transplantation will be performed on Visit 6. BonoFill will be administrated to the subject in a single session at one tested cell dose. |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2014-06-03
- Last updated
- 2017-01-12
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT02153268. Inclusion in this directory is not an endorsement.